- ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)
This study is looking at a new combination of medicines for some types of cancer, called MK-4280A and pembrolizumab. It wants to see how well these medicines shrink tumours and if they help people feel better. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
France · Italy · Netherlands - recruitingNA
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
This study looks at how well a new blood test, called a liquid biopsy, can find genetic changes in cancer. It compares this blood test to the usual way of testing cancer tissue to see if the blood test can help doctors make better treatment plans.
France - recruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
United States · Australia · Canada - active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
United States · Australia · Belgium - authorisedPhase I and Phase II (Integrated)- Other
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
This study looks at a new medicine, Ifinatamab Deruxtecan, for children aged 1 month to under 12 years with certain cancers that haven't responded to other treatments. It aims to see how safe it is and if it helps shrink tumors or stop them from growing.
France · Spain · Sweden